Danske Bank A S boosted its stake in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 8.4% during the 3rd quarter, Holdings Channel reports. The firm owned 52,242 shares of the medical research company’s stock after acquiring an additional 4,040 shares during the quarter. Danske Bank A S’s holdings in Labcorp were worth $16,096,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Allied Private Wealth LLC purchased a new position in shares of Labcorp in the second quarter worth $33,000. William Mack & Associates Inc. purchased a new stake in shares of Labcorp during the third quarter valued at $42,000. Pathway Financial Advisers LLC purchased a new stake in shares of Labcorp during the third quarter valued at $43,000. Jones Financial Companies Lllp acquired a new position in shares of Labcorp in the 2nd quarter valued at $58,000. Finally, Ancora Advisors LLC purchased a new stake in Labcorp during the 2nd quarter valued at about $67,000. Institutional investors and hedge funds own 95.94% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on LH. UBS Group raised their price objective on Labcorp from $380.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Morgan Stanley reiterated an “overweight” rating and issued a $388.00 target price on shares of Labcorp in a research report on Thursday, October 29th. HSBC upgraded shares of Labcorp from a “hold” rating to a “buy” rating and set a $410.00 price target on the stock in a report on Thursday, November 5th. Piper Sandler raised their price target on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, Truist Financial lifted their price objective on shares of Labcorp from $365.00 to $395.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Labcorp has an average rating of “Moderate Buy” and an average price target of $369.08.
Read Our Latest Research Report on Labcorp
Insider Buying and Selling at Labcorp
In related news, EVP Brian J. Caveney sold 2,000 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president directly owned 34,562 shares of the company’s stock, valued at approximately $12,858,446.48. This represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richelle P. Parham sold 1,078 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $361.22, for a total transaction of $389,395.16. Following the completion of the transaction, the director directly owned 2,288 shares in the company, valued at $826,471.36. This trade represents a 32.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,384 shares of company stock valued at $1,241,707 over the last ninety days. Corporate insiders own 0.84% of the company’s stock.
Labcorp Stock Down 0.9%
Labcorp stock opened at $368.93 on Wednesday. The firm has a market cap of $29.96 billion, a price-to-earnings ratio of 30.26, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86. Labcorp Holdings Inc. has a 52 week low of $245.00 and a 52 week high of $375.10. The business’s 50-day moving average price is $331.39 and its 200 day moving average price is $293.59. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60.
Labcorp (NYSE:LH – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $4.18 earnings per share. Labcorp’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.51 earnings per share for the current year.
Labcorp Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio is presently 23.63%.
Labcorp Profile
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Further Reading
- Five stocks we like better than Labcorp
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
